2. Academic Validation
  3. STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model

STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model

  • Cells. 2020 Mar 15;9(3):722. doi: 10.3390/cells9030722.
Byung-Hak Kim 1 2 3,  Haeri Lee 1 2,  Cheol Gyu Park 4,  Ae Jin Jeong 1 2,  Song-Hee Lee 1 2,  Kum Hee Noh 1 2,  Jong Bae Park 5,  Chung-Gi Lee 3,  Sun Ha Paek 6 7 8,  Hyunggee Kim 4,  Sang-Kyu Ye 1 2 8 9
Affiliations

Affiliations

  • 1 Department of Pharmacology, Seoul National University College of Medicine, Seoul 03080, Korea.
  • 2 Biomedical Science Project (BK21PLUS), Seoul National University College of Medicine, Seoul 03080, Korea.
  • 3 CYTUS H&B Corporation, Cheongju 28159, Korea.
  • 4 Department of Biotechnology, School of Life Sciences and Biotechnology, Korea University, Seoul 02841, Korea.
  • 5 Department of System Cancer Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Korea.
  • 6 Department of Neurosurgery, Seoul National University College of Medicine, Seoul 03080, Korea.
  • 7 Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea.
  • 8 Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul 03080, Korea.
  • 9 Neuro-Immune Information Storage Network Research Center, Seoul National University College of Medicine, Seoul 03080, Korea.
PMID: 32183406 DOI: 10.3390/cells9030722
Abstract

Constitutively activated STAT3 plays an essential role in the initiation, progression, maintenance, malignancy, and drug resistance of Cancer, including glioblastoma, suggesting that STAT3 is a potential therapeutic target for Cancer therapy. We recently identified ODZ10117 as a small molecule inhibitor of STAT3 and suggested that it may have an effective therapeutic utility for the STAT3-targeted Cancer therapy. Here, we demonstrated the therapeutic efficacy of ODZ10117 in glioblastoma by targeting STAT3. ODZ10117 inhibited migration and invasion and induced apoptotic cell death by targeting STAT3 in glioblastoma cells and patient-derived primary glioblastoma cells. In addition, ODZ10117 suppressed stem cell properties in glioma stem cells (GSCs). Finally, the administration of ODZ10117 showed significant therapeutic efficacy in mouse xenograft models of GSCs and glioblastoma cells. Collectively, ODZ10117 is a promising therapeutic candidate for glioblastoma by targeting STAT3.

Keywords

ODZ10117; STAT3; glioblastoma; glioma stem cell (GSC); targeted therapy.

Figures
Products
Inhibitors & Agonists
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-13919
    98.85%, STAT3 Inhibitor
Other Products